These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 22773741

  • 21. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 22. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y, Lu J, Dong M, Wu D, Zhu Y, Li Q, Chen C, Li Z.
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
    [Abstract] [Full Text] [Related]

  • 23. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H, Lv Y, Wang D, Xue J, Yan Z.
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [Abstract] [Full Text] [Related]

  • 24. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
    Newman D, Scheetz MH, Adeyemi OA, Montevecchi M, Nicolau DP, Noskin GA, Postelnick MJ.
    Ann Pharmacother; 2007 Oct; 41(10):1734-9. PubMed ID: 17726066
    [Abstract] [Full Text] [Related]

  • 25. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C, Cotta MO, Muller L, Wallis SC, Lipman J, Lefrant JY, Roberts JA.
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [Abstract] [Full Text] [Related]

  • 26. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 27. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
    Tomaselli F, Dittrich P, Maier A, Woltsche M, Matzi V, Pinter J, Nuhsbaumer S, Pinter H, Smolle J, Smolle-Jüttner FM.
    Br J Clin Pharmacol; 2003 Jun; 55(6):620-4. PubMed ID: 12814459
    [Abstract] [Full Text] [Related]

  • 28. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP.
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [Abstract] [Full Text] [Related]

  • 29. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
    Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL.
    J Clin Pharmacol; 2009 Jul; 49(7):816-23. PubMed ID: 19443680
    [Abstract] [Full Text] [Related]

  • 30. Concentrations of piperacillin-tazobactam in human jaw and hip bone.
    Al-Nawas B, Kinzig-Schippers M, Soergel F, Shah PM.
    J Craniomaxillofac Surg; 2008 Dec; 36(8):468-72. PubMed ID: 18783957
    [Abstract] [Full Text] [Related]

  • 31. Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.
    Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2780-4. PubMed ID: 7695262
    [Abstract] [Full Text] [Related]

  • 32. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.
    Clin Infect Dis; 2015 May 15; 60(10):1462-71. PubMed ID: 25670823
    [Abstract] [Full Text] [Related]

  • 33. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2009 Nov 15; 34(5):429-33. PubMed ID: 19726163
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2002 May 15; 22(5):569-77. PubMed ID: 12013355
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
    Murao N, Ohge H, Ikawa K, Watadani Y, Uegami S, Shigemoto N, Shimada N, Yano R, Kajihara T, Uemura K, Murakami Y, Morikawa N, Sueda T.
    Int J Antimicrob Agents; 2017 Sep 15; 50(3):393-398. PubMed ID: 28694230
    [Abstract] [Full Text] [Related]

  • 36. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE, Golden JA, McIver M, Little E, Zurlinden E.
    Int J Antimicrob Agents; 2007 Nov 15; 30(5):422-7. PubMed ID: 17716873
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
    Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A.
    BMC Infect Dis; 2017 Apr 28; 17(1):314. PubMed ID: 28454524
    [Abstract] [Full Text] [Related]

  • 38. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H, Protocol 023 Study Group.
    Infect Dis Obstet Gynecol; 2003 Apr 28; 11(1):27-37. PubMed ID: 12839630
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.
    Pharmacotherapy; 2015 Jun 28; 35(6):600-7. PubMed ID: 26095008
    [Abstract] [Full Text] [Related]

  • 40. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
    D'Agostino C, Rhodes NJ, Skoglund E, Roberts JA, Scheetz MH.
    J Infect Chemother; 2015 Oct 28; 21(10):742-6. PubMed ID: 26143049
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.